CD8A and neoplasm: Importantly, Winograd et al. demonstrated that this combined regimen not only induces tumor rejection in a CD8+ T-cell-dependent manner, but also increases the capability of mice to reject subsequent tumor insults, suggesting that an anti-tumor immune memory with high therapeutic potential is generated.